{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:23Z","timestamp":1793968283502,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA214278"],"award-info":[{"award-number":["P01CA214278"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016520"],"award-info":[{"award-number":["P30CA016520"]}],"id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102977","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:33:57Z","timestamp":1786034037000},"page":"102977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models"],"prefix":"10.1016","volume":"28","author":[{"given":"Giulia","family":"Golinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatuna","family":"Gabunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley V.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-2730","authenticated-orcid":false,"given":"Charles-Antoine","family":"Assenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He N.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Gonzalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-2838","authenticated-orcid":false,"given":"Sofia","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Reff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-0164","authenticated-orcid":false,"given":"David","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4172-0399","authenticated-orcid":false,"given":"Deeksha","family":"Muthumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Verrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Masciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Santori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-1579","authenticated-orcid":false,"given":"Julia","family":"Tchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1503","authenticated-orcid":false,"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-9449","authenticated-orcid":false,"given":"Regina M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9725-6277","authenticated-orcid":false,"given":"John","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102977_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-cancerbio-061421-012235","article-title":"Stalled CARs: mechanisms of resistance to CAR T cell therapies","volume":"7","author":"Salas-Benito","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102977_bib0003","first-page":"853","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0004","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0005","first-page":"119","article-title":"Boosting engineered T cells","volume":"365","author":"Singh","year":"2019","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0006","first-page":"162","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0007","first-page":"446","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0008","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940674","article-title":"Next generation CD40 agonistic antibodies for cancer immunotherapy","volume":"13","author":"Salomon","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0011","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"21","author":"Smith","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jcyt.2026.102977_bib0012","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","article-title":"CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies","volume":"19","author":"Bullock","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0014","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/10495","article-title":"CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy","volume":"5","author":"Diehl","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cancers13061302","article-title":"Agonistic CD40 antibodies in cancer treatment","volume":"13","author":"Djureinovic","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0016","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102977_bib0017","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1078-0432.CCR-06-1893","article-title":"Prospect of targeting the CD40 pathway for cancer therapy","volume":"13","author":"Vonderheide","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.605619","article-title":"Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer","volume":"11","author":"Vonderheide","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0019","first-page":"1612","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science (1979)"},{"key":"10.1016\/j.jcyt.2026.102977_bib0020","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102977_bib0021","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-OT2-17-01","article-title":"Abstract OT2-17-01: phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer","volume":"83","author":"Reddy","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0022","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","article-title":"Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer","volume":"78","author":"Rech","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0023","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","article-title":"Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors","volume":"14","author":"Rudqvist","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102977_bib0024","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102977_bib0025","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2026.102977_bib0026","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1038\/s41467-021-23832-3","article-title":"Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102977_bib0027","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0028","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0029","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0031","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0032","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102977_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102977_bib0034","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jcyt.2026.102977_bib0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11523-018-0567-0","article-title":"The role of mesothelin as a diagnostic and therapeutic target in pancreatic ductal adenocarcinoma: a comprehensive review","volume":"13","author":"Nichetti","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2026.102977_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102977_bib0038","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102977_bib0042","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4049\/jimmunol.1600146","article-title":"CSF-1R-dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy","volume":"197","author":"Byrne","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0043","doi-asserted-by":"crossref","first-page":"eabi7083","DOI":"10.1126\/sciimmunol.abi7083","article-title":"Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy","volume":"6","author":"Siwicki","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jcyt.2026.102977_bib0039","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-021-02750-4","article-title":"Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy","volume":"19","author":"Zhang","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0040","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1038\/s41467-020-19833-3","article-title":"CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function","volume":"11","author":"Kuhn","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102977_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102977_bib0045","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.immuni.2026.03.011","article-title":"Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the microenvironment","volume":"59","author":"Maltez","year":"2026","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102977_bib0046","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcyt.2026.102977_bib0047","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102977_bib0048","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-25-0663","article-title":"Targeted lipid nanoparticle delivery of FAP-CAR mRNA enables potent in vivo T-cell engineering against pancreatic tumors","volume":"14","author":"Bajbouj","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0049","article-title":"Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors","volume":"1877","author":"Akbari","year":"2022","journal-title":"Biochim Biophys Acta: Rev Cancer"},{"key":"10.1016\/j.jcyt.2026.102977_bib0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102977_bib0051","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102977_bib0052","doi-asserted-by":"crossref","first-page":"e177141","DOI":"10.1172\/jci.insight.177141","article-title":"Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment","volume":"9","author":"Hatae","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2026.102977_bib0053","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102977_bib0054","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003264","article-title":"The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation","volume":"10","author":"Sum","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102977_bib0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/2326-6066.CIR-14-0182","article-title":"Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage","volume":"3","author":"Medina-Echeverz","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005718","article-title":"Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity","volume":"11","author":"Pfefferle","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102977_bib0057","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","article-title":"Fibroblast activation protein alpha-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity","volume":"27","author":"Sum","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102977_bib0058","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat Cancer"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:22:41Z","timestamp":1793967761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926009382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1465324926009382"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102977","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102977"}}